{"id":521139,"date":"2021-08-02T08:03:14","date_gmt":"2021-08-02T12:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/"},"modified":"2021-08-02T08:03:14","modified_gmt":"2021-08-02T12:03:14","slug":"vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/","title":{"rendered":"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Aug.  02, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wu9CKKoc0fvhWChMYhAvl71xDfM5-1WyDXV71Or0x4759xCO0mYPzI5I78fznBiNplQ_Z56T_rgegMNUm_mGgQM1byzRJ-BUYqBjjEakw7U=\" rel=\"nofollow noopener\" target=\"_blank\">VistaGen Therapeutics<\/a> (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (\u201cCNS\u201d) disorders, today announced that management will participate in the Canaccord Genuity 41st Annual Growth Conference including a fireside chat with Shawn Singh, Chief Executive Officer, on Wednesday, August 11 at 1:30 p.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference.<\/p>\n<p>A live webcast of VistaGen\u2019s presentation will be accessible through the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6L4P0Jo0Ne8EyaMgSFK5Zf0E1o1lmKA9angP8vqMiRh37X0jAGioeNHtNrLxGLv02Js65amh6jP6yRGpBLwJU-8PmXJnvEANE0Z6rSx2o_w=\" rel=\"nofollow noopener\" target=\"_blank\">News\/Events<\/a> page of the Investors section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=08TEKRB6i6AhjrZcl5xtq9QHkb1sTpY1NTkQds2ODUPzZApSLm-_vUzIyWbq-6WxeywSeH2oW_J0Z3N-61gjhg==\" rel=\"nofollow noopener\" target=\"_blank\">www.VistaGen.com<\/a>.<\/p>\n<p>\n        <strong>About VistaGen<\/strong><br \/>\n        <br \/>VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen&#8217;s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=08TEKRB6i6AhjrZcl5xtq8p-8yqEdUF1wCAKOAqIdj-xlx9Hk7HdeR9QiScXI3UDYTxOfw3lJQMHofvnezUTcA==\" rel=\"nofollow noopener\" target=\"_blank\">www.VistaGen.com<\/a>\u00a0and connect with VistaGen on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YnjjFa4yx-C_lzkNBIF0BmeD6hiunJqDj9qdoaXTDa-242Xf9cizjfzlzjHQHIHRWm0bDL0Dkp6EUIX9CVtxxw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fUDoH8jW6-5vDfEMLwafg5RgCpXb9G095AmUJIHsqYmcWbinHWKrGibhrRlKRLKvV0sA05sdehjtZbeIKv1tP0-bZ1f2RWwuoAnPEr0n_DjTgIjZ1r5ydqyFNI9j63wp\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fvOE-8H2EbQdJtkqqG8o2bC5d3CatmxJyREbkyLgH7A7kNQEdGcna1Bkrv4rlJ9DcZPSaYoP042fkimluv5gFw==\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>VistaGen Company Contacts<\/strong><br \/>\n        <br \/>\n        <em>Media:<\/em><br \/>\n        <br \/>Mark McPartland<br \/>Phone: (650) 577-3606<br \/>Email: IR@vistagen.com<\/p>\n<p>\n        <em>Investor:<\/em><br \/>\n        <br \/>Mark Flather<br \/>Phone: (650) 577-3617<br \/>Email: IR@vistagen.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/30aac703-c6f0-4e5d-8398-7dcd7f14ad66\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (\u201cCNS\u201d) disorders, today announced that management will participate in the Canaccord Genuity 41st Annual Growth Conference including a fireside chat with Shawn Singh, Chief Executive Officer, on Wednesday, August 11 at 1:30 p.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference. A live webcast of VistaGen\u2019s presentation will be accessible through the News\/Events page of the Investors section of the Company\u2019s website at www.VistaGen.com. About VistaGen VistaGen Therapeutics is a biopharmaceutical company &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-521139","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (\u201cCNS\u201d) disorders, today announced that management will participate in the Canaccord Genuity 41st Annual Growth Conference including a fireside chat with Shawn Singh, Chief Executive Officer, on Wednesday, August 11 at 1:30 p.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference. A live webcast of VistaGen\u2019s presentation will be accessible through the News\/Events page of the Investors section of the Company\u2019s website at www.VistaGen.com. About VistaGen VistaGen Therapeutics is a biopharmaceutical company &hellip; Continue reading &quot;VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-02T12:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference\",\"datePublished\":\"2021-08-02T12:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"wordCount\":224,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/\",\"name\":\"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=\",\"datePublished\":\"2021-08-02T12:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (\u201cCNS\u201d) disorders, today announced that management will participate in the Canaccord Genuity 41st Annual Growth Conference including a fireside chat with Shawn Singh, Chief Executive Officer, on Wednesday, August 11 at 1:30 p.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference. A live webcast of VistaGen\u2019s presentation will be accessible through the News\/Events page of the Investors section of the Company\u2019s website at www.VistaGen.com. About VistaGen VistaGen Therapeutics is a biopharmaceutical company &hellip; Continue reading \"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-02T12:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference","datePublished":"2021-08-02T12:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/"},"wordCount":224,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/","name":"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=","datePublished":"2021-08-02T12:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3NiM0MzI0Njg4IzIyMDQzODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vistagen-therapeutics-to-participate-in-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=521139"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521139\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=521139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=521139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=521139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}